[go: up one dir, main page]

BR0113165A - Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados - Google Patents

Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados

Info

Publication number
BR0113165A
BR0113165A BR0113165-6A BR0113165A BR0113165A BR 0113165 A BR0113165 A BR 0113165A BR 0113165 A BR0113165 A BR 0113165A BR 0113165 A BR0113165 A BR 0113165A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
related methods
pyrimidinamine derivatives
cell death
pyrimidinamine
Prior art date
Application number
BR0113165-6A
Other languages
English (en)
Inventor
Elfrida R Grant
Frank K Brown
Robert Allan Zivin
Michael Mcmillan
Zhong Zhong
Malcom Scott
Allen B Reitz
Tina Morgan Ross
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0113165A publication Critical patent/BR0113165A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE 4-PIRIMIDINAMINA, COMPOSIçõES FARMACêUTICAS E MéTODOS RELACIONADOS". A invenção provê novos derivados 4-pirimidinamina neuroprotetores e composições farmacêuticas neuroprotetoras compreendendo 4-pirimidinaminas. Esta invenção também provê métodos para usar estas composições para evitar morte de célula isquêmica, particularmente morte de célula neuronal, e reduzir a possibilidade de morte de célula neuronal em um indivíduo devido a um evento traumático. Finalmente, esta invenção provê um aparelho para a administração a um indivíduo das presentes composições farmacêuticas.
BR0113165-6A 2000-08-08 2001-08-06 Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados BR0113165A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379100P 2000-08-08 2000-08-08
PCT/US2001/024659 WO2002012198A2 (en) 2000-08-08 2001-08-06 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
BR0113165A true BR0113165A (pt) 2003-07-15

Family

ID=22837982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113165-6A BR0113165A (pt) 2000-08-08 2001-08-06 Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados

Country Status (16)

Country Link
US (3) US20030008883A1 (pt)
EP (1) EP1313713B1 (pt)
JP (1) JP2004505952A (pt)
CN (1) CN1468225A (pt)
AR (1) AR031601A1 (pt)
AT (1) ATE398109T1 (pt)
AU (1) AU2001281120A1 (pt)
BR (1) BR0113165A (pt)
CA (1) CA2419030A1 (pt)
DE (1) DE60134414D1 (pt)
HK (1) HK1054033A1 (pt)
IL (1) IL154240A0 (pt)
MX (1) MXPA03001226A (pt)
NZ (1) NZ524100A (pt)
WO (1) WO2002012198A2 (pt)
ZA (1) ZA200301868B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011472A (es) * 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
AU2004259712A1 (en) * 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamine analogues
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005054231A1 (en) * 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US7534798B2 (en) * 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1763526B1 (en) 2004-06-28 2009-06-24 Bayer Schering Pharma AG 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
CA2584167A1 (en) 2004-10-22 2006-05-04 Amgen Inc. Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
JP5733839B2 (ja) * 2010-03-26 2015-06-10 国立大学法人北海道大学 神経変性疾患治療薬
CA2882733C (en) * 2012-08-23 2021-07-27 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents
DK3080103T3 (en) * 2013-12-11 2018-07-30 Biogen Ma Inc BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
US11440899B2 (en) * 2017-10-17 2022-09-13 Merck Patent Gmbh Pyrimidine TBK/IKKe inhibitor compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068271A (en) * 1988-09-21 1991-11-26 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
EP0723533A1 (en) * 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
ES2221440T3 (es) * 1998-10-16 2004-12-16 Daiichi Suntory Pharma Co Ltd Derivados de acido aminofenoxiacetico como neuroprotectores.
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体

Also Published As

Publication number Publication date
ATE398109T1 (de) 2008-07-15
US20030008883A1 (en) 2003-01-09
NZ524100A (en) 2005-01-28
ZA200301868B (en) 2004-06-25
DE60134414D1 (de) 2008-07-24
US20030212079A1 (en) 2003-11-13
AU2001281120A1 (en) 2002-02-18
US20040006094A1 (en) 2004-01-08
MXPA03001226A (es) 2004-09-10
EP1313713B1 (en) 2008-06-11
JP2004505952A (ja) 2004-02-26
WO2002012198A3 (en) 2002-06-06
CA2419030A1 (en) 2002-02-14
WO2002012198A2 (en) 2002-02-14
AR031601A1 (es) 2003-09-24
EP1313713A2 (en) 2003-05-28
CN1468225A (zh) 2004-01-14
IL154240A0 (en) 2003-07-31
HK1054033A1 (zh) 2003-11-14

Similar Documents

Publication Publication Date Title
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
UY26130A1 (es) Compuestos para tratar la obesidad
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
SE0001899D0 (sv) New compounds
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR0109107A (pt) Usos terapêuticos de mediadores ppar
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR9811099A (pt) Inibidores de urocinase
DE60019334D1 (de) Antivirale arznei
AR034343A1 (es) Combinaciones farmaceuticas
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
PT1150704E (pt) Melagatran para o tratamento da inflamacao
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
DE60003074D1 (de) Fusidinsäure-derivate
ECSP003812A (es) Compuestos de dihidropirimidina hererociclicos
PT1165596E (pt) Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: JOHNSON & JOHNSON (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6AE7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.